JP5480804B2 - リポ酸誘導体を含有する医薬製剤 - Google Patents

リポ酸誘導体を含有する医薬製剤 Download PDF

Info

Publication number
JP5480804B2
JP5480804B2 JP2010504247A JP2010504247A JP5480804B2 JP 5480804 B2 JP5480804 B2 JP 5480804B2 JP 2010504247 A JP2010504247 A JP 2010504247A JP 2010504247 A JP2010504247 A JP 2010504247A JP 5480804 B2 JP5480804 B2 JP 5480804B2
Authority
JP
Japan
Prior art keywords
ion
lipoic acid
pharmaceutical formulation
pairing agent
acid derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010504247A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524963A (ja
JP2010524963A5 (enExample
Inventor
ロバート ジー．エル． ショール，
ラジンデール バシン，
ロバート ジェイ． ロドリゲス，
Original Assignee
コーナーストーン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーナーストーン ファーマシューティカルズ，インコーポレーテッド filed Critical コーナーストーン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2010524963A publication Critical patent/JP2010524963A/ja
Publication of JP2010524963A5 publication Critical patent/JP2010524963A5/ja
Application granted granted Critical
Publication of JP5480804B2 publication Critical patent/JP5480804B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicinal Preparation (AREA)
JP2010504247A 2007-04-18 2008-04-17 リポ酸誘導体を含有する医薬製剤 Expired - Fee Related JP5480804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91260507P 2007-04-18 2007-04-18
US60/912,605 2007-04-18
PCT/US2008/060650 WO2008131114A2 (en) 2007-04-18 2008-04-17 Pharmaceutical formulations containing lipoic acid derivatives

Publications (3)

Publication Number Publication Date
JP2010524963A JP2010524963A (ja) 2010-07-22
JP2010524963A5 JP2010524963A5 (enExample) 2012-05-31
JP5480804B2 true JP5480804B2 (ja) 2014-04-23

Family

ID=39872894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504247A Expired - Fee Related JP5480804B2 (ja) 2007-04-18 2008-04-17 リポ酸誘導体を含有する医薬製剤

Country Status (19)

Country Link
US (4) US20080262077A1 (enExample)
EP (1) EP2144609B1 (enExample)
JP (1) JP5480804B2 (enExample)
KR (1) KR101539785B1 (enExample)
CN (1) CN101820875B (enExample)
AR (1) AR067309A1 (enExample)
AU (1) AU2008242827B2 (enExample)
BR (1) BRPI0810439B1 (enExample)
CA (1) CA2684479C (enExample)
CL (1) CL2008001124A1 (enExample)
ES (1) ES2528414T3 (enExample)
IL (1) IL201581A (enExample)
MX (1) MX2009011165A (enExample)
NZ (1) NZ580973A (enExample)
PL (1) PL2144609T3 (enExample)
PT (1) PT2144609E (enExample)
SA (1) SA08290240B1 (enExample)
TW (1) TWI459944B (enExample)
WO (1) WO2008131114A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
BRPI0821176A2 (pt) * 2008-03-04 2015-10-06 Robert Rodriguez modulador do estado de fosforilação de pelo menos um complexo de enzimas, método para modular o complexo de pdh em um paciente que apresenta uma doença, condição, ou síndrome e método pra diagnosticar e predizer benefício em um paciente que apresenta sintomas de uma doença, condição, ou síndrome causada por uma alteração da estrutura e/ou da atividade do complexo de pdh
CN102056605A (zh) * 2008-04-04 2011-05-11 罗伯特·绍尔 药物组合物
CA2745383A1 (en) * 2008-12-01 2010-06-10 In Vasc Therapeutics, Inc. Compositions comprising renin-angiotensin aldosterone system inhibitors and lipoic acid compounds, and the use thereof for the treatment of renin-angiotensin aldosterone system related disorders
WO2010110771A2 (en) * 2009-03-25 2010-09-30 Frank Gibson Substituted thiol-containing alkyl fatty acids and process for synthesizing derivatives thereof
CA2782676C (en) 2009-12-01 2021-06-15 Shire Human Genetic Therapies, Inc. Pharmaceutical compositions for intracellular delivery of nucleic acids and proteins and uses thereof for treatment of ureca cycle metabolic disorders
WO2011143590A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
WO2011143593A1 (en) * 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
CA3107288A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CN102657606B (zh) * 2012-05-25 2014-01-01 江苏神龙药业有限公司 一种供静脉给药用的硫辛酸注射液
EP2859102A4 (en) 2012-06-08 2016-05-11 Shire Human Genetic Therapies NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
US20150322103A1 (en) * 2012-12-19 2015-11-12 Cornerstone Pharmaceuticals, Inc. Pharmaceutical compounds
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
MX365409B (es) 2013-03-14 2019-05-31 Shire Human Genetic Therapies Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados.
CN103360437B (zh) * 2013-04-27 2015-10-21 江苏教育学院 一种硫辛酸糖类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN103497344B (zh) * 2013-09-25 2015-09-23 深圳先进技术研究院 用于负载贵金属颗粒的纳米凝胶及其制备方法与应用
EP3060303B1 (en) 2013-10-22 2018-11-14 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
KR20250005450A (ko) 2014-04-25 2025-01-09 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna 의 정제 방법
WO2015195070A1 (en) * 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
AU2014398233B2 (en) * 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
TW202114651A (zh) * 2019-08-16 2021-04-16 美商拉斐爾製藥公司 用於治療癌症之方法及含有４，６—雙（苄硫基）己酸之藥物組成物
US20230092232A1 (en) * 2020-02-28 2023-03-23 University Of Florida Research Foundation, Incorporated Compounds that modulate anti-tumor immunity and methods of doing the same
JP2023549086A (ja) * 2020-11-03 2023-11-22 コーナーストーン ファーマシューティカルズ，インコーポレーテッド デビミスタットを使用して胆道癌を治療するための治療法及び組成物
CN119770650A (zh) * 2025-01-09 2025-04-08 华中科技大学 一种硫辛酸-胆碱离子液体溶液及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805251A (en) * 1953-07-22 1957-09-03 Ethyl Corp Preparation of aryloxyaliphatic acids and salts thereof
GB758897A (en) 1953-10-19 1956-10-10 Merck & Co Inc Thio-substituted aliphatic carboxylic acids and their preparation
US3002011A (en) * 1953-12-04 1961-09-26 Merck & Co Inc Intermediates and processes for producing alpha-lipoic acid
US2809978A (en) * 1953-12-04 1957-10-15 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2980716A (en) * 1954-06-11 1961-04-18 Research Corp Method for preparing 6, 8-dihalooctanoic esters
US2975198A (en) * 1954-07-08 1961-03-14 Research Corp Lipoic acid intermediates
US2852531A (en) * 1954-09-24 1958-09-16 Merck & Co Inc Tris-(2-tetrahydropyranyl) esters of 6, 8-bis (hydrocarbonmercapto)-4, 4-dicarboxy-5-ocaprylic acid and preparation thereof
US2875238A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2875239A (en) * 1957-02-19 1959-02-24 Merck & Co Inc Intermediates useful in the synthesis of alpha-lipoic acid
US2985685A (en) * 1959-01-26 1961-05-23 American Cyanamid Co Alkanolamine aluminates as catalysts for ester redistribution
US3453312A (en) * 1966-04-27 1969-07-01 Merck & Co Inc (beta - (substituted-thio) - acylphenoxy)-alkanoic acids and (beta-(substitutedthio) acylphenylmercapto) alkanoic acids and derivatives thereof
US3345368A (en) * 1967-02-15 1967-10-03 American Cyanamid Co Substituted 7-acetylamino cephalosporanic acids
US3881017A (en) * 1973-05-18 1975-04-29 Ciba Geigy Corp 9-Thiaprostaglandin compositions
DE2422498A1 (de) * 1973-05-18 1974-12-05 Ciba Geigy Ag Neue thiaprostaglandine und verfahren zu ihrer herstellung
JPS5323539Y2 (enExample) * 1973-11-30 1978-06-17
DE3512911A1 (de) * 1985-04-11 1986-10-16 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
US5344941A (en) * 1986-09-03 1994-09-06 Samour Carlos M Water soluble salts of thionaphthene-2-carboxylic acid
DE4000397A1 (de) * 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
US5750141A (en) * 1993-04-08 1998-05-12 The University Of Queensland Administration of vaso-active agent and therapeutic agent
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
EP1486495B1 (en) * 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
US7320797B2 (en) * 2003-08-29 2008-01-22 Bioderm Research Antiaging cosmetic delivery systems
JP2007077066A (ja) * 2005-09-14 2007-03-29 Shiseido Co Ltd 不全角化抑制剤、毛穴縮小剤
US20090036356A1 (en) * 2006-03-06 2009-02-05 Avestha Gengraine Technologies Pvt. Ltd. Octanoic acid derivatives as dipeptidyl peptidase inhibitors
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
MX2009011165A (es) 2007-04-18 2009-12-09 Cornerstone Pharmaceuticals In Formulaciones farmaceuticas que contienen derivados del acido lipoico.
KR101644192B1 (ko) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. 리포산 유도체

Also Published As

Publication number Publication date
AU2008242827A1 (en) 2008-10-30
EP2144609B1 (en) 2014-10-29
EP2144609A4 (en) 2010-06-16
US8691873B2 (en) 2014-04-08
EP2144609A2 (en) 2010-01-20
AR067309A1 (es) 2009-10-07
CL2008001124A1 (es) 2009-01-02
CN101820875A (zh) 2010-09-01
KR20100029744A (ko) 2010-03-17
WO2008131114A3 (en) 2010-01-21
MX2009011165A (es) 2009-12-09
BRPI0810439B1 (pt) 2021-06-29
IL201581A (en) 2016-04-21
PT2144609E (pt) 2015-02-06
BRPI0810439A2 (pt) 2014-10-07
US20120178812A1 (en) 2012-07-12
HK1140424A1 (en) 2010-10-15
JP2010524963A (ja) 2010-07-22
TW200901964A (en) 2009-01-16
WO2008131114A2 (en) 2008-10-30
US20080262077A1 (en) 2008-10-23
IL201581A0 (en) 2010-05-31
US20170056355A1 (en) 2017-03-02
US9320726B2 (en) 2016-04-26
PL2144609T3 (pl) 2015-04-30
SA08290240B1 (ar) 2012-02-22
CA2684479A1 (en) 2008-10-30
KR101539785B1 (ko) 2015-07-27
AU2008242827B2 (en) 2014-06-05
US9872845B2 (en) 2018-01-23
ES2528414T3 (es) 2015-02-10
CN101820875B (zh) 2014-07-23
CA2684479C (en) 2017-11-14
US20150011633A1 (en) 2015-01-08
TWI459944B (zh) 2014-11-11
NZ580973A (en) 2011-10-28

Similar Documents

Publication Publication Date Title
JP5480804B2 (ja) リポ酸誘導体を含有する医薬製剤
US11065335B2 (en) Methods of treating leukemia using compositions containing bis(benzylthio)octanoic acid and ion pairs thereof
JP5412423B2 (ja) リポ酸誘導体
JP2010524963A5 (enExample)
HK1140424B (en) Pharmaceutical formulations containing lipoic acid derivatives
US20220184212A1 (en) Pharmaceutical formulations containing lipoic acid derivatives
JPWO2015037659A1 (ja) 水溶液製剤及びその製造方法
CN104415033B (zh) 取代唑类化合物作为制备抗肿瘤药物的应用
JPWO2012063487A1 (ja) アラレマイシン又はその誘導体を有効成分とする抗マラリア薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130522

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140214

R150 Certificate of patent or registration of utility model

Ref document number: 5480804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees